Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-cash Items (2021 - 2024)

Inhibikase Therapeutics (IKT) has disclosed Non-cash Items for 3 consecutive years, with $31.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Non-cash Items changed N/A to $31.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $31.1 million, a N/A change, with the full-year FY2024 number at $31.1 million, changed N/A from a year prior.
  • Non-cash Items was $31.1 million for Q4 2024 at Inhibikase Therapeutics, up from $300000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $31.1 million in Q4 2024 to a low of $300000.0 in Q4 2022.
  • A 3-year average of $11.1 million and a median of $2.0 million in 2021 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 85.0% in 2022; the steepest drop was 85.0% in 2022.
  • Inhibikase Therapeutics' Non-cash Items stood at $2.0 million in 2021, then plummeted by 85.0% to $300000.0 in 2022, then surged by 10266.67% to $31.1 million in 2024.
  • Per Business Quant, the three most recent readings for IKT's Non-cash Items are $31.1 million (Q4 2024), $300000.0 (Q4 2022), and $2.0 million (Q4 2021).